For the Inventor, By the Inventor

Enter assignee name

Boulder, CO, United States of America

Array Biopharma Inc.

USPTO Granted Patents = 329

CIPO Patents = 284

EPO Patents = 137

Trademarks = 6

Forward Citations = 2,492

Loading Chart...

Loading Chart...

601 inventors (with patents filed for the assignee):

James F Blake (105 out of 112 patents)

Eli M Wallace (79 out of 91 patents)

Joseph P Lyssikatos (66 out of 139 patents)

4. Yutong Jiang (64 out of 68 patents)

5. Steven Wade Andrews (64 out of 97 patents)

6. Julia Haas (61 out of 64 patents)

7. Gabrielle R Kolakowski (50 out of 58 patents)

8. Qian Zhao (48 out of 62 patents)

9. Shelley Allen (42 out of 44 patents)

10. Mark Joseph Chicarelli (40 out of 44 patents)

11. Adam Wade Cook (36 out of 41 patents)

12. David A Moreno (35 out of 39 patents)

13. Tony P Tang (34 out of 40 patents)

14. Li Ren (32 out of 40 patents)

15. Kevin Ronald Condroski (32 out of 42 patents)

Core Competencies:

Pharmaceutical Composition

Protein Tyrosine Phosphatase Inhibitors

FGFR Tyrosine Kinases

RET Kinase Inhibitors

KRas G12D Inhibitors

HER2 Inhibitors

BRAF-Associated Diseases

TAM Kinases

Pyrazolo Compounds

ErbB Type I Receptor

Macrocyclic Compounds

Point Mutations in TRK

329 patents: Sort by Forward Citations

1. 12465593 - Pharmaceutical composition (2025-11-11),

2. 12364684 - Pharmaceutical composition (2025-07-22),

3. 12351571 - Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases (2025-07-08),

4. 12318367 - Pharmaceutical composition (2025-06-03),

5. 12220403 - Pharmaceutical composition (2025-02-11),

6. 12187721 - Protein tyrosine phosphatase inhibitors (2025-01-07),

7. 12180207 - Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases (2024-12-31),

8. 12171739 - N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases (2024-12-24),

9. 11998545 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2024-06-04),

10. 11964989 - KRas G12D inhibitors (2024-04-23),

11. 11964988 - Fused heterocyclic compounds as RET kinase inhibitors (2024-04-23),

12. 11932633 - KRas G12C inhibitors (2024-03-19),

13. 11884664 - Protein tyrosine phosphatase inhibitors (2024-01-30),

14. 11851434 - Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors (2023-12-26),

15. 11834453 - Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors (2023-12-05),

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other diseases. Array has multiple drug candidates in clinical trials, with a strong focus on oncology. Their innovative approach and expertise in drug discovery and clinical development have positioned them as a leader in the field. For more information, visit their website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

329 Patents

#1 in Boulder, CO

#21 in Colorado

#1,296 in US

#2,659 in the World

Boulder, CO, United States of America

Array Biopharma Inc.

Forward Citations = 2,492

601 inventors:

James F Blake (105 out of 112 patents)

Eli M Wallace (79 out of 91 patents)

Joseph P Lyssikatos (66 out of 139 patents)

4. Yutong Jiang (64 out of 68 patents)

5. Steven Wade Andrews (64 out of 97 patents)

Please report any incorrect information to support@idiyas.com

Loading…